REGENXBIO Secures $100M Milestone as Diabetic Retinopathy Drug Enters Phase IIb/III Trial
RGNX has more than doubled off its 52-week low of $5.455 on elevated volume (2.8× avg).
Summary
REGENXBIO is set to receive a $100 million milestone payment from AbbVie, triggered by the first patient dosing in the Phase IIb/III NAAVIGATE trial for its diabetic retinopathy gene therapy, surabgene lomparvovec. This significant cash infusion, expected in July 2026, is particularly impactful given the company's recent Q1 loss and reiterated going concern doubts. Advancing sura-vec into a late-stage Phase IIb/III trial marks a major positive development for the company's pipeline. Topline pivotal trial data for sura-vec is anticipated in Q4 2026.
At the time of this announcement, RGNX was trading at $11.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $541.8M. The 52-week trading range was $5.46 to $16.19. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.